CGON - CG Oncology, Inc. Common stock
NEXT EARNINGS:
Mar 27, 2026
(in 30 days)
EPS Est: $-0.61
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$79.00
DETAILS
HIGH:
$93.00
LOW:
$70.00
MEDIAN:
$75.00
CONSENSUS:
$79.00
UPSIDE:
35.41%
Market Cap:
4.71B
Volume:
798,564
Avg Volume:
1,054,405
52 Week Range:
14.8-59.08
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.34
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
113
IPO Date:
2024-01-25
EPS (TTM):
-1.41
P/E Ratio:
-20.36
Revenue (TTM):
1.14M
Total Assets:
754.80M
Total Debt:
238,000
Cash & Equiv:
257.07M
Rev Growth (5Y):
-52.1%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-15.6%
Debt/Equity:
0.00
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-14 | $-0.57 | $-0.56 | -2.0% | $1.7M | $59364 | +2706.4% |
| 2025-08-08 | $-0.54 | $-0.49 | -10.2% | — | $81620 | — |
| 2025-05-13 | $-0.45 | $-0.39 | -15.4% | $52000 | $118170 | -56.0% |
| 2025-03-28 | $-0.48 | $-0.41 | -17.1% | $456000 | $123950 | +267.9% |
| 2024-08-08 | $-0.28 | $-0.42 | +33.3% | $111000 | — | — |
| 2024-05-09 | $-0.36 | $-0.35 | -2.9% | $529000 | — | — |
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 1.14M | 204,000 | 191,000 | 10.36M |
| Net Income | (88.04M) | (48.61M) | (35.44M) | (12.84M) |
| EPS | -1.41 | -1.02 | -0.66 | -0.28 |
| Total Assets | 754.80M | 199.30M | 147.75M | 58.69M |
| Total Debt | 238,000 | 1.03M | 15.94M | 15.13M |
| Cash & Equivalents | 257.07M | 8.27M | 88.14M | 53.61M |
| Operating Cash Flow | (78.71M) | (45.68M) | (29.80M) | (13.65M) |
| Free Cash Flow | (78.95M) | (45.68M) | (29.82M) | (13.75M) |
| FCF per Share | -1.26 | -0.69 | -0.45 | -0.21 |
| Book Value | 733.38M | 184.79M | 125.18M | 40.25M |
| Cash & ST Investments | 742.00M | 187.67M | 143.48M | 53.61M |
| ROC Equity | -0.12 | -0.26 | -0.28 | -0.32 |